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(57) ABSTRACT 
In accordance with exemplary embodiments, apparatus and 
method for biologic sample rapid collection and recovery 
device, and convenient storage are provided. An exemplary 
embodiment includes an apparatus comprising a lateral flow 
technology device including at least a membrane configured 
to bind an analyte from a sample that flows through the lateral 
flow technology device, in which a selected portion of the 
membrane bound to the analyte when placed directly in an 
analysis system does not substantially inhibit analysis of the 
analyte. An elution protocol is not required to extract the 
analyte bound from the selected portion before placed 
directly in the analysis system. 
6 Claims, 7 Drawing Sheets 
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APPARATUS AND METHOD FOR BIOLOGIC 
SAMPLE RAPID COLLECTION AND 
RECOVERY DEVICE, AND CONVENIENT 
STORAGE 
2 
the art for an LFT device configured for collecting (also 
known as sampling, fixing, or binding) the analyte that may 
be placed directly in an analysis system for analysis, such as 
by the PCR or ELISA technique, without the eluting step 
FIELD OF THE INVENTION 
This invention relates to apparatus and method for biologic 
sample rapid collection and recovery device, and convenient 
storage that includes, but is not limited to, collecting, storing 
and recovering nucleic acid from a microorganism. 
5 intervening. Eliminating the eluting step would speed and 
simplify the collection of specimens for molecular-clinical 
diagnostics. The apparatus and method embodied by the 
claims finds application when sampling specimens for 
molecular-clinical diagnostics in human health, veterinary 
10 health, plant health, biosecurity ( e.g., surveillance and 
response), defense, forensics, microbial forensics, and food 
quality and biosecurity, among other fields of study. BACKGROUND 
Polymerase chain reaction ("PCR") is a powerful molecu- 15 
lar biology technique used to copy, i.e., amplify, specific 
nucleic acid sequences within template deoxyribonucleic 
acid ("DNA"), whether derived from native DNA or cDNA 
reverse transcribed from ribonucleic acid ("RNA"). An entire 
PCR assay is carried out in a single tube containing a mixture 20 
of enzyme, template, primers, and substrates. Each amplifi-
cation cycle starts with denaturation (which includes at least 
heating) that is followed by annealing and then elongation 
(also known as synthesis and polymerization) reactions. 
The PCR assay, in which the cycle of denaturing, annealing 25 
and synthesizing reactions is typically repeated 20 or more 
times, can be divided into three phases: exponential when the 
PCR reaction product doubles during every cycle (assuming 
100% reaction efficiency); linear when the reaction compo-
nents are consumed, and the reaction product growth slows 30 
and degrades; and plateau when the reaction product growth 
stops and degrades. In traditional (also known as End-Point, 
or classic) PCR, detection and quantitation of the amplified 
sequence, i.e., the reaction product, are performed in the 
plateau phase. In real-time PCR, the amount of PCR reaction 35 
product is detected and measured at each cycle during the 
exponential growth phase, which enables determination of 
the initial amount of DNA template with great precision. 
Enzyme-linked immunosorbent assay ("ELISA") is a com-
monly used diagnostic technique, in which an enzyme is 40 
coupled directly to an antibody. The antibody bound to an 
unknown amount of antigen can be quantitated indirectly by 
measuring the conversion by the enzyme of an ELISA sub-
strate to a product. A detectable signal can permit real-time 
determination of the ELISA reaction rate, e.g., a color change 45 
can be used to quantify enzyme reaction through photometric 
adsorbency measurement. 
Lateral flow technology ("LFT") assay ( also known simply 
as strip-test) has been a popular platform for diagnostic tests 
since its introduction in the late 1980s, e.g., the human early 50 
pregnancy test. LFT assay has been used for qualitative or 
semi-quantitative detection of specific analytes including 
antigens and antibodies, hence other common names for LFT 
assay: lateral flow immunoassay and immunochromato-
graphic strip test. Biologic sample for LFT assay may be 55 
derived from whole blood, serum, plasma, saliva, urine, feces, 
wound exudate, soil, dust, vegetation, food, or other suitable 
source. Even products of nucleic acid amplification systems, 
such as PCR reaction products, can be studied by LFT assay. 
LFT assay can be run in a single step using the biologic 60 
sample in a variety oftest locations, such as laboratory, agri-
cultural field, crime scene, etc. Several analytes can be tested 
simultaneously on the same strip. 
The prior art requires a burdensome and time consuming 
step of eluting ( also known as extracting) an analyte from an 65 
LFT device before performing the PCR or ELISA technique 
on the analyte collected by LFT assay. There exists a need in 
SUMMARY OF THE INVENTION 
In accordance with exemplary embodiments, apparatus 
and method for biologic sample rapid collection and recovery 
device, and convenient storage are provided. 
An exemplary embodiment includes an apparatus compris-
ing a lateral flow technology ("LFT") device including at 
least a membrane configured to bind an analyte from a sample 
that flows through the LFT device, in which a selected portion 
of the membrane bound to the analyte when placed directly in 
an analysis system does not substantially inhibit analysis of 
the analyte. 
An alternative exemplary embodiment includes an appara-
tus comprising an LFT system including at least a membrane 
configured to bind an analyte from a sample that flows 
through the LFT system, such that the LFT system facilitates 
a period of storage of the analyte bound to the membrane and 
does not substantially inhibit analysis of the analyte bound to 
the membrane when placed in an analysis system after the 
period of storage. 
Another exemplary embodiment includes a method com-
prising, the steps of: flowing a sample solution that contains 
an analyte through an LFT device configured to bind the 
analyte; punching a sample disc that binds the analyte from 
the LFT device; and placing the sample disc directly in an 
analysis system for analysis of the analyte, in which the step 
of placing the sample disc is not preceded by a step of eluting 
the analyte from the sample disc. 
These and various other features and advantages that char-
acterize the claimed invention will be apparent upon reading 
the following detailed description and upon review of the 
associated drawings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows plan view of an exemplary lateral flow tech-
nology device. 
FIG. lA illustrates a sectional view taken along the line 
lA-lA of FIG. 1. 
FIG. 2 shows plan view of another exemplary lateral flow 
technology device. 
FIG. 2A illustrates a sectional view taken along the line 
2A-2A of FIG. 2. 
FIG. 3 shows plan view of an alternate exemplary lateral 
flow technology device. 
FIG. 3A illustrates a sectional view taken along the line 
3A-3A of FIG. 3. 
FIG. 4A portrays a plan view of a portion of an exemplary 
direct format lateral flow technology assay before the assay is 
run. 
FIG. 4B depicts a plan view of a portion of the exemplary 
direct format lateral flow technology assay after the assay is 
run and the result is positive. 
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FIG. 4C reveals a plan view of a portion of the exemplary 
direct format lateral flow technology assay after the assay is 
run and the result is negative. 
4 
FIG. SA portrays a plan view of a portion of an alternate 
exemplary competitive format lateral flow technology assay 5 
before the assay is run. 
FIG. 2 shows another exemplary embodiment of the LFT 
device 10 with a conjugate pad 18 disposed between the 
sample pad 12 and the membrane 14. As illustrated in the FIG. 
2A sectional view, the LFT assay is run by bringing the 
sample 26 in contact, e.g., in the sample application direction 
28, with the sample pad 12 of the LFT device 10. The sample 
FIG. SB depicts a plan view of a portion of the alternate 
exemplary competitive format lateral flow technology assay 
after the assay is run and the result is negative. 
FIG. SC reveals a plan view of a portion of the alternate 10 
exemplary competitive format lateral flow technology assay 
after the assay is run and the result is positive. 
26 flows (in the flow direction 34) through the sample pad 12 
to the conjugate pad 18, where the particulate conjugate 30 
has been immobilized. The sample 26 mobilizes the particu-
late conjugate 30, and the analyte 32 in the sample 26 interacts 
with the particulate conjugate 30 as they flow (in the flow 
direction 34) into the membrane 14. Some portion of the 
particulate conjugate 30 and the analyte 32 may become fixed FIG. 6 shows an exemplary embodiment where a selected 
portion of the membrane is placed directly in a PCR test tube 
of an analysis system. 
FIG. 7 shows an exploded view of an exemplary lateral 
flow technology device with an optional cassette. 
FIG. 8 shows an SEM picture of bacteria on water soluble 
paper. 
15 
in the membrane 14. The excess of the sample 26, including 
the analyte 32, and the particulate conjugate 30 not fixed to 
the membrane 14 flow (in the flow direction 34) towards the 
wick 16 where they are entrapped. The conjugate pad 30 is 
optional. 
FIG. 9 is a graphic representation of absorbance readings 20 
for different water soluble papers. 
FIG. 3 portrays an alternative embodiment of the LFT 
device 10, in which a specimen filter 36 is disposed between 
the sample pad 12 and the membrane 14. As shown in the FIG. 
3A sectional view, the specimen filter 36 is configured to 
collect a sample debris 38 from the sample 26 while allowing 
FIG. 10 is a graphical representation of absorbance read-
ings for different amounts of water. 
FIG. 11 is a graphical representation of absorption times 
for different water soluble papers. 
FIG. 12 is a graphical representation of absorption time for 
different amounts of water. 
DETAILED DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
Detailed descriptions of the exemplary embodiments are 
provided herein. It is to be understood, however, that the 
invention embodied in the claims may take various forms. 
Various aspects of the invention may be inverted, or changed 
in reference to specific part shape and detail, part location, or 
part composition. In addition, the figures shown are not drawn 
to scale. Therefore, specific details disclosed herein are not to 
25 the analyte 32 to flow (in the flow direction 34) from the 
sample pad 12 through the specimen filter 36 to the membrane 
14 and into the wick 16 when the sample 26 is brought in 
contact, e.g., in the sample application direction 28, with the 
sample pad 12 of the LFT device 10. The absorbed fluid of the 
30 sample 26 flows (in the flow direction 34) through the speci-
men filter 36 to help separate the specimen fractions, e.g., the 
analyte 32, and cell debris, e.g., the sample debris 38, by size. 
The specimen filter 36 is optional. 
FIGS. l-3A demonstrate various embodiments; however, it 
35 will be understood that alternative embodiments can be uti-
be interpreted as limiting, but rather as a basis for the claims 
and as a representative basis for teaching one skilled in the art 40 
to employ the invention embodied in the claims in virtually 
any appropriately detailed system, structure or manner. 
lized, e.g., any embodiment may or may not have the 
unmounted portion 24 of the membrane 14. Similarly, any of 
the various embodiments can have the holder 46 ( as shown in 
FIGS. 2-2A) configured for handling the LFT device 10 or 
providing a label space for the LFT device 10. 
Lateral Flow Technology Assay Formats 
OVERVIEW 
FIG. 1 shows an exemplary configuration of a lateral flow 
technology ("LFT") device 10 that includes at least a sample 
pad 12, a membrane 14, and a wick 16. FIG. lA sectional 
view depicts the sample pad 12, the membrane 14, and the 
wick 16 overlap one another and are mounted on a backing 
card 20, such as with an adhesive 22, e.g., a pressure-sensitive 
adhesive, therebetween. In one embodiment a MIBA-020 
backing card with an adhesive coating is used. As discussed 
below, it has been found that an unmounted portion 24 of the 
membrane 14 produces useful characteristics. 
An LFT assay is run by bringing a sample 26 in contact, 
e.g., in a sample application direction 28, with the sample pad 
12 of the LFT device 10. The sample 26 flows (in a flow 
direction 34) through the sample pad 12 into the membrane 
14. Some portion of an analyte 32 in the sample 26 may 
become fixed in the membrane 14. The sample 26, including 
the analyte 32, not fixed to the membrane 14 flow (in the flow 
direction 34) towards the wick 16 where the sample 26, 
including the analyte 32, are entrapped (also known as 
absorbed). In certain embodiments, the sample 26 is a bio-
logic sample and the analyte 32 is nucleic acid from a micro-
organism. 
The LFT device 10 can further include either direct (also 
45 known as sandwich technique), competitive (also known as 
inhibition technique), or "boulders in the stream" format LFT 
assay, as readily known to those skilled in the art. However, 
these assay formats are optional. 
FIGS. 4A-C illustrate a portion of the LFT device 10 show-
50 ing the conjugate pad 18 and the membrane 14. FIG. 4A 
represents the LFT device 10 before the direct format LFT 
assay is run. FIG. 4B shows the LFT device 10 after the assay 
is run (in the flow direction 34) for a positive result. A test line 
40 is visible ( depicted as black) and a control line 42 is visible. 
55 FIG. 4C portrays the LFT device 10 after the assay is run (in 
the flow direction 34) for a negative result. The test line 40 is 
invisible (depicted as bounded by broken lines) and the con-
trol line 42 is visible. 
FIGS. SA-C illustrate a portion of the LFT device 10 show-
60 ing the conjugate pad 18 and the membrane 14. FIG. SA 
represents the LFT device 10 before the competitive format 
LFT assay is run. FIG. SB shows the LFT device 10 after the 
assay is run (in the flow direction 34) for a negative result. The 
test line 40 is visible and the control line 42 is visible. FIG. SC 
65 portrays the LFT device 10 after an assay is run (in the flow 
direction 34) for a positive result. The test line 40 is invisible 
and the control line 42 is visible. 
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Further details regarding LFT technology are given below, 
and the book Lateral Flow Immunoassay edited by Raphael 
Wong and Harley Tse, Humana Press (2009) provides further 
information and is incorporated by reference herein. 
6 
ASW-15, which has 50 µm thickness;ASW-25, which has 83 
µm thickness; ASW-50, which has 76 µm thickness; ASW-
DC, which has 50 µm thickness; and ASW-240, which has 
170 µm thickness. However, other material with suitable 
Membrane 
One purpose of the membrane 14 (also known as analytical 
region, reaction membrane, or matrix membrane) in the LFT 
device 10 is to bind the analyte 32, such as protein, antigen, 
antibody, nucleic acid, or microorganism. 
5 characteristics disclosed may be utilized for the membrane 
14. The more preferred SCMC cards from the above five 
SCMC cards are ASW-15, ASW-25 and ASW-50, because 
these SCMC cards did not substantially inhibit PCR up to a 
fifth order of magnitude dilution of a test using plasmid-
10 fungal DNA. The starting solution is diluted four times for a 
total of five concentrations, i.e., A=l0 ng/µl; B=l ng/µl; 
C=0.1 ng/µl; D=0.01 ng/µl; E=0.001 ng/µl; F=is negative 
control, water only no DNA. 
Traditionally, nitrocellulose has been the material of 
choice for the membrane 14 in the vast majority of LFT 
devices 10. Other traditional materials for the membrane 14 
have included nylon and polyvinylidene fluoride. Nitrocellu- 15 
lose has flaws, such as flammability and breakage problems 
when the membrane 14 does not adhere to the backing card 
20. The traditional materials have shelf-life longevity issues. 
In addition, the analyte 32 sampled by the LFT device 10 must 
be extracted from the membrane 14 made of these traditional 20 
Conjugate Pad 
The role of the conjugate pad 18 (as shown in FIGS. 2-2A) 
in the LFT device 10 includes accepting the particulate con-
jugate 30, holding the particulate conjugate 30 stable over 
shelflife (preferably up to 2 years) of the LFT device 10, and 
releasing the particulate conjugate 30 efficiently and repro-
ducibly when the LFT assay is run. As the skilled artisan will 
know, it is often necessary to pretreat the conjugate pad 18 to 
assure optimal release and stability of the particulate conju-
materials (nitrocellulose, nylon, polyvinylidene fluoride, 
etc.) by the burdensome and time-consuming process of elu-
tion in order for the analyte 32 to be analyzed in an analysis 
system, such as those using the PCR or ELISA technique, 
such as is described in (I) IUPAC Gold Book: eluent. Inter-
national Union of Pure and Applied Chemistry, www.gold-
book.iupac.org/E02040.htm1. Retrieved 2008-09-28; (2) 
Brown, Phillis (2001). Advances in chromatography. CRC 
Press. pp. 36. ISBN 082470509; and (3) Elution. www.en-
.wikipedia.org/wiki/Eiution; each of which are hereby incor-
porated by reference. 
25 gate 30. 
Materials of choice for the conjugate pad 18 are glass fiber, 
polyester or Rayon. In an exemplary embodiment, the conju-
gate pad 18 is made from nitrocellulose. For the best results, 
the materials for the conjugate pad 18 should be hydrophilic 
30 and allow rapid flow rates. 
However, it has been found that by selecting an appropriate 
material that does not substantially inhibit ( or interfere with 
The particulate conjugate 30 may be adsorbed with anti-
bodies or antigens that are specific to the analyte 32 to be 
collected. A label for the particulate conjugate 30 may include 
colloidal gold or monodisperse latex, tagged with either a 
35 visual or a fluorescent dye. The labels can be read qualita-
tively or quantitatively after the assay is run. 
or impede) PCR, the membrane 14 may be placed directly 
into End-Point PCR mixtures, reverse transcription PCR mix-
tures, real-time PCR mixtures, without the eluting step inter-
vening and variants of these methods. Alternatively, the mem-
brane 14 may be placed directly, without the eluting step 
intervening, in an analysis system using the ELISA tech-
nique. In other words, the membrane 14 collects the analyte 40 
32 in the LFT device 10 when the LFT assay is run, and the 
membrane 14 acts a carrier of the analyte 32 into the PCR or 
ELISA system, or other suitable analysis system. 
As shown in FIG. 6, after the LFT assay has been run (in the 
flow direction 34) from the sample pad 12 to the wick 16, a 45 
membrane disc (also known as a "punch" or "selected por-
tion" or "sample disc") 48 is obtained from the membrane 14 
made of a suitable biomaterial in an exemplary embodiment. 
The punch 48 is a selected portion of the membrane 14, e.g., 
As previously mentioned, the conjugate pad is optional. 
Sample Pad 
The role of the samplepad12 (e.g., as showninFIGS.1-3A 
and 6) in the LFT device 10 includes accepting the sample 26, 
treating the sample 26 such that it is compatible with the LFT 
device 10, and releasing with high-efficiency the analyte 32 
into the rest of the LFT device 10, e.g. the membrane 14. The 
sample pad 12 must be able to accept in a controlled way all 
of the fluid volume from the sample 26, thereby helping to 
channel the fluid into the assay materials (such as the conju-
gate pad 18, the membrane 14, and the wick 16) rather than 
allowing flooding or surface flow. Sample treatments for the 
sample pad 12 include filtering unwanted particulates, chang-
ing the pH, binding sample components that can inhibit run-
ning the LFT assay, and disrupting sample components, such 
as mucins, to release the analyte 32 to the LFT device 10. In 
1.2 millimeter ("mm") diameter piece obtained with a What- 50 
man® Harris Uni-Core™ 1.2 mm ("puncher"), which is 
placed directly into a PCR tube ( depicted as 50) or an ELISA 
microplate well of the PCR or ELISA analysis system, 
respectively. Other suitable sizes and shapes for the punch 48 
may be used in various embodiments. 55 some embodiments, the sample pad 12 and the conjugate pad 
18 can be the same component. In a particular exemplary embodiment, the membrane 14 is 
made from a water soluble paper, e.g., Aquasol® Water 
Soluble Paper is a unique product made of sodium carboxy 
methyl cellulose ("SCMC") and wooden pulp that dissolves 
in cold water, hot water, steam and most aqueous solutions. In 60 
addition, Aquasol® Water Soluble Paper is described as non-
toxic, environmentally friendly, and 100% biodegradable. 
Aquasol® Water Soluble Paper can be obtained fromAquasol 
Corporation (North Tonawanda, N.Y. USA). 
Water soluble paper containing SCMC is available in a 65 
variety of SCMC cards that can be used to make the mem-
brane 14. SCMC cards evaluated for the membrane 14 are 
Tensile strength while the sample pad 12 is wet from the 
sample 26 is an important criterion used in selecting the 
material for the sample pad 12. In an exemplary embodiment, 
the fluid volume of the sample 26 used to run the LFT assay 
is 0.5 milliliters ("ml"), or 500 microliters ("µl"). 
Examples of materials used for the sample pad 12 are 
cellulose, glass fiber, Rayon, and other filtration media. In 
exemplary embodiments, the sample pad 12 is made from 
Whatman GB002, Standard 17, or GF33 (from Whatman pie, 
UK); or Millipore C083 (from Millipore in Billerica, Mass. 
USA). 
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Wick 
The wick 16 (e.g., as shown in FIGS. l-3A and 6) acts as 
the engine of the LFT device 10 while running the LFT assay 
8 
width 62 of the plastic cassette 58 is a cassette width of 20 
mm. The cassette 58 is optional. 
In the exemplary embodiment, the cassette 58 has an upper 
housing member 64 and a lower housing member 66. The 
upper housing member 64 has an attachment element 68 
(shown in partial cutaway) and correspondingly the lower 
to pull fluid from the sample 26 added to the LFT device 10 5 
into the wick 16 and hold the fluid for the durationofthe assay 
and in an exemplary embodiment for the duration of storage 
until recovery of the analyte 32 by the punch 48 from the 
membrane 14. The wick 16 should not release fluid back into 
the membrane 14 or false positive results may occur. 
housing member 66 has an engagement element 70. The 
attachment element 68 and the engagement member 70 may 
be reversed between the upper housing member 64 and the 
10 lower housing member 66. The attachment element 68 can 
reversibly engage the engagement element 70 for contain-
ment of the LFT device 10 by the housing 58. The upper 
housing member 64 and the lower housing member 66 may 
The wick 16 is typically made from high-density cellulose, 
which is generally selected for absorptive capacity and tensile 
strength. An exemplary wick 16 is made from Millipore 
C083. 
"Wicking rate" or "capillary rise time" is defined as the 
time required for a fluid front of the sample 26 to traverse the 
distance from the sample pad 12 through the membrane 14 to 
absorption at the wick 16. Wicking rate is an important crite-
rion when selecting the materials for making the sample pad 
12, the membrane 14, the wick 16, etc. In an exemplary 
embodiment, the wicking rate is chosen to be less than the 
time for the membrane 14 made from water soluble paper to 
dissolve in the fluid of the sample 26. 
Specimen Filter 
The role of the specimenfilter36 (as shown in FIGS. 3-3A) 
is separation of the specimen fractions, e.g., the analyte 32, 
and the cell debris, e.g., the sample debris 38. The specimen 
filter may be made from a variety of materials known to one 
skilled in the art. In an exemplary embodiment, the specimen 
filter 36 is made from nitrocellulose. 
The specimen filter 36 is optional. The sample pad 12 may 
provide some of the filtration function that could be provided 
by the specimen filter 36. 
Backing Card 
The role of the backingcard20 (as showninFIGS. lA, 2A, 
and 3A) includes providing rigidity to the LFT device 10, 
which eases handling of the LFT device. The backing card 20 
can be made from polystyrene or other plastics, or other 
suitable material. In an exemplary embodiment, the backing 
card 20 is made from Part# MIBA-020 obtained from Diag-
nostic Consulting Network (Carlsbad, Calif. USA). 
Next, actual examples of the LFT device and components 
are described below. 
Exemplary Lateral Flow Device 
FIG. 7 portrays an exemplary embodiment in exploded 
view of the LFT device 10 surrounded by a cassette (also 
known herein as "housing") 58. The sample pad 12 and wick 
15 
have a plurality of attachment elements 68 and engagement 
elements 70, respectively. 
The upper housing member 64 has a well 72 for receiving 
fluid from the sample 26 and a well aperture 7 4 at the base of 
the well 72 for releasing fluid into the sample pad 12. The well 
20 72 may receive 0.5 ml of fluid without overflowing. A rim 76 
of the well aperture 7 4 may be biased into the sample 12 when 
the cassette 58 contains the LFT device 10 so that fluid from 
the sample 26 does not flood or surface flow the LFT device 
10. 
25 The upper housing member 64 has a membrane window 78 
through which LFT assay results may be viewed without 
opening the cassette 58 containing the LFT device 10. In 
addition, the punch 48 from the membrane 14 can be obtained 
without opening the cassette 58. In the MIBA-0120, S (la-
30 beled 80) for the sample 26, T (labeled82) for the test line 40, 
and C (labeled 84) for the control line 42 are provided. A 
gripping area 86 is provided, also. 
The lower housing member 66 has a sample guide 88 that 
35 
facilitates biasing the sample pad 12 towards the well aperture 
74 when the LFT device 10 is contained within the cassette 
58. The pedestal 90 facilitates biasing the membrane 14 
towards the membrane window 78 when the LFT device 10 is 
contained within the cassette 58, which promotes efficiently 
40 obtaining the punch 48. A wick guide 92 provides lateral 
support to the LFT device 10 adjacent the wick 16 to help 
maintain positions of the sample pad 12 and the membrane 14 
relative to the well aperture 74 and the membrane window 78, 
45 
respectively. 
In the exemplary embodiment of the LFT device 10, the 
width 94 of each of the sample pad 12, the membrane 14, the 
wick 16, and the backing card 20 is 4 mm; the length 96 of the 
sample pad 12 is 26 mm; the length 98 of the membrane 14 is 
25 mm; the length 100 of the wick 16 is 21 mm; and the length 
50 110 of the backing card 20 is 67 mm. The sample pad 12 has 
an unmounted portion 102 that overlaps the membrane 14 by 
2.5 mm at the first end 104 of the membrane 14. The remain-
ing 23.5 mm of the sample pad 12 is mounted to the backing 
16 are made from Millilpore C083. The membrane 14 is made 
from Aquasol ASW-25. The backing card 20 is made from 55 
MIBA-020. The fluid volume of the sample 26 used for the 
exemplary embodiment is 0.5 ml. The wicking rate is 
approximately 3 minutes, i.e., 2.94 minutes, as measured by 
the mean of ten test runs of the sample 26 through the LFT 
device 10 for the time required for a fluid front of the sample 60 
26 to traverse from the bottom of the sample pad 12 to the top 
card 20 by the adhesive 22. The wick 16 has an unmounted 
portion 106 that overlaps the membrane 14 by 2.5 mm at the 
second end 108 of the membrane 14. The remaining 18.5 mm 
of the wick 16 is mounted to the backing card 20 by the 
adhesive 22. The first end 104 and the second 108 are 
mounted to the backing card 20 by the adhesive 22, while the 
unmounted portion 24, which in this exemplary embodiment 
has a length of20 mm, of the membrane 14 is not adherent to 
of specimen filter, i.e., a 50 mm travel distance. The average 
speed is 1 7 mm/min. 
In the exemplary embodiment, the plastic cassette 58 is 
MICA-0120 sold by Diagnostic Consulting Network (Carls- 65 
bad, Calif.), herein incorporated by reference. The outside 
length 60 of the plastic cassette 58 is 69 mm. The outside 
the backing card 20. 
The unmounted portion 24 facilitates obtaining the punch 
48 (as shown in FIG. 6) of the membrane 14 without the 
backing card 20 (shown in FIG. 6) adherent. The punch 48 
thus obtained may be placed directly in the analysis system 
for analysis of the analyte 32 without first needing to elute the 
US 9,423,398 B2 
9 
analyte 32 from the punch 48, when the backing card 20 
adherent to the punch 48 could interfere with analysis of the 
analyte 32. 
When the plurality of attachment members 68 of the upper 
housing member 64 are correspondingly coupled to the plu- 5 
rality of the engagement members 70 of the lower housing 
member 66 upon closing the plastic cassette 58, the LFT 
device 10 is held relatively immobile in a protective container 
that promotes convenient storage. In preferred embodiments, 
the LFT device 10 conveniently stores the analyte 32 col- 10 
lected on the membrane 14 for at least 1 month, 3 months, 6 
months, 12 months, 18 months, or 24 months at room tem-
perature (-23° C.), in a refrigerator (-4° C.), in a freezer 
(--20° C.), or in a deep freezer (--80° C.), or in some 
15 
combination of temperatures. To present positive storage has 
been determined for eight months for types of soluble mem-
brane at all temperatures. Considering the observed good 
yields of DNA it is projected at least 24 months of storage. 
After the convenient storage, the analyte 32 is reliably recov- 20 
ered by the punch 48 and carried to the analysis where the 
analyte 32 is analyzed in the analysis system. 
In other words, an exemplary embodiment of an apparatus 
has an LFT system including at least a membrane 14 config-
ured to bind an analyte 32 from a sample 26 that flows through 25 
the LFT system, such that the LFT system facilitates a period 
of storage of the analyte 32 bound to the membrane 14 and 
does not substantially inhibit analysis of the analyte 32 bound 
to the membrane 14 when placed in an analysis system after 
the period of storage. A second embodiment includes a 30 
selected portion 48 of the membrane 14 is water soluble paper 
placed directly in the analysis system for analysis of the 
analyte 32.A third embodiment includes the period of storage 
10 
The water soluble paper was studied for the ability to bind 
(or fix) bacteria, i.e., analyte 32, to the soluble paper using 
SEM analysis. Due to the solubility properties of water 
soluble paper, fixation of bacteria 32 in water soluble paper 
had some challenges. However, bacteria 32 could be trapped 
in the water soluble paper, particularly in the crevices (see 
FIG. 8). 
An embodiment includes a storage crevice of the mem-
brane 14 configured to bind the analyte 32.A second embodi-
ment includes the storage crevice is absent before the sample 
flows through the membrane 14. 
In a particular exemplary embodiment, the membrane 14 is 
made from a water soluble paper, e.g., Aquasol® Water 
Soluble Paper is a unique product made of sodium carboxy 
methyl cellulose ("SCMC") and wooden pulp that dissolves 
in cold water, hot water, steam and most aqueous solutions. 
Water soluble paper containing SCMC is available in a vari-
ety of SCMC cards that can be used to make the membrane 
14. SCMC cards evaluated for the membrane 14 areASW-15, 
ASW-25,ASW-50,ASW-DC, andASW-240. However, other 
material with suitable characteristics disclosed may be uti-
lized for the membrane 14. The more preferred SCMC cards 
from the above five SCMC cards areASW-15, ASW-25 and 
ASW-50, because these SCMC cards did not substantially 
inhibit PCR up to a fifth order of magnitude dilution of a test 
using plasmid-fungal DNA. The starting solution is diluted 
four times for a total of five concentrations, i.e., A=l0 ng/µl; 
B=l ng/µl; C=0.1 ng/µl; D=0.01 ng/µl; E=0.001 ng/µl; F=is 
negative control, water only, no DNA. 
The punch 48 taken from the unmounted portion 24 of 
membrane 14 (as also seeninFIG. lA) can be placed directly 
into the analysis system when the membrane 14 is made from 
material that does not interfere with the analysis technique, 
such as the PCR or ELISA technique. Thus, the exemplary 
embodiment yields a robust apparatus and method for bio-
logic sample that reduces, and may eliminate, the need of 
tedious extraction protocols for the analyte 32. 
In other words, an exemplary embodiment is an apparatus 
having an LFT device 10 including at least a membrane 14 
configured to bind an analyte 32 from a sample 26 that flows 
through the LFT device 10, in which a selected portion 48 of 
is substantially at a predetermined temperature chosen from a 
group consisting of room temperature, refrigeration, freez- 35 
ing, and deep freezing. A fourth embodiment includes the 
period of storage is at least 3 months before the selected 
portion 48 is placed directly in the analysis system, and the 
analysis system includes at least an analysis technique 
selected from a group consisting of PCR and ELISA. 40 the membrane 14 bound to the analyte 32 when placed 
directly in an analysis system does not substantially inhibit 
analysis of the analyte 32. A second embodiment includes an 
elution protocol is not required to extract the analyte 3 2 bound 
from the selected portion 48 before placed directly in the 
Punch from Water Soluble Paper 
It has been found that the appropriately selected membrane 
45 analysis system. A third embodiment includes the selected 
portion 48 of the membrane 14 is water soluble paper. A 
fourth embodiment includes the analysis system includes at 
least an analysis technique selected from a group consisting 
of PCR and ELISA. A fifth embodiment includes the selected 
14 can capture the analyte 32 of interest, yet still present the 
analyte 32 for analysis in the analysis system while not sub-
stantially inhibiting the analytic technique. An exemplary 
embodiment of such a membrane 14 is water soluble paper. 
Various water soluble papers with different thicknesses were 
tested. It was found that the thickest material has more residue 50 
portion 48 of the membrane 14 includes at least sodium 
carboxy methyl cellulose. A sixth embodiment includes the 
selected portion 48 of the membrane 14 bound to the analyte 
32 is placed directly in the analysis system without elution of 
the analyte 32 from the membrane 14, and the analysis system 
includes at least an analysis technique selected from a group 
as seen by higher absorption reading. In addition, the thickest 
material absorbed water faster than the thinnest material. The 
application of water produced no perforation, fissures, crack-
ing, holes or breakage in the water soluble paper even with the 
test water volume increased to 10 µI. 55 consisting of PCR and ELISA. 
In another embodiment, the LFT device 10 further com-
prises at least a backing card 20 adherent to a mounted portion 
(such as first 104 or second end 108) of the membrane 14, in 
which the membrane 14 includes the mounted portions (104, 
60 108) and an unmounted portion 24 that is not adherent to the 
backing card 20, and the selected portion 48 is selected from 
the unmounted portion 24 of the membrane 14. 
A scanning electron microscope ("SEM") was used to 
determine the surface appearance of water soluble paper in 
the previously wet versus dry states, and to assess water 
soluble paper looking for the presence of pore spaces, or 
crevices, that may serve as storage pockets for the analyte 32, 
such as a microorganism or nucleic acid. A small piece of 
water soluble paper ( dry versus previously wet by 10 µL water 
then allowed to dry) was treated with gold-palladium coating 
and viewed under SEM at magnification=l00x, Spot=3.0, 
and HV=l0.00 kV. It was found that the organization of the 65 
paper fibers in the previously wet water soluble paper is more 
scattered than in the dry water soluble paper. 
Analyte Collection 
In an exemplary embodiment of the LFT device 10, run-
ning the LFT assay collects a portion of the analyte 32, e.g., 
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microorganism, from the sample 26 in the membrane 14. 
Immobilizing specific antibodies to the analyte 32 in the LFT 
device 10 can increase the analyte 32 collected. Antibodies 
can be immobilized in a number of combinations on either the 
conjugate pad 18 or the membrane 14, which can satisfy 5 
current and/or future technical requirements, applications or 
special demands of the market. 
To increase the likelihood for a true positive result, rather 
than a false negative, by the analysis technique, such as PCR 
or ELISA, the punch 48 is obtained from a high yield area of 10 
the membrane 14. The high yield areas for the punch 48 
include the membrane 14 in the test line 40 (as seen in FIGS. 
4B and SC) that is positive by immunoassay. 
In other words, another embodiment includes the LFT 
15 
device 10 further includes at least a biologic marker, in which 
the biologic marker is configured to concentrate the analyte 
32 in a predetermined sample collection region (such as the 
test line 40 that is positive, or other biologic marker location) 
by an assay format chosen from a group consisting of direct, 20 
competitive, and boulder in the stream. Another embodiment 
can include the biologic marker is a specific antibody targeted 
to the analyte 32. 
Another high yield area of the membrane 14 for the punch 
48 is a first portion 52 of the unmounted portion 24 of the 25 
membrane 14, as seen in FIG. 6. The best location to take the 
punch 48 is the first 2 mm of the membrane closer to the 
sample pad 12. The sample 26 becomes more filtered by 
sampling within the membrane 14 closer to the wick 16. Inan 
exemplary embodiment, the first portion 52 is the first 5 mm 30 
of the unmounted portion 24 closest to the sample pad 12, 
when the unmounted portion 24 length (identified as 54) is 20 
mm and width (identified as 56) is 4 mm. In a further exem-
plary embodiment, the membrane 14 is sampled within the 
first 2 mm of the unmounted portion 24 nearest the sample 35 
pad 12. 
Method for Analysis of Analyte Including Lateral 
Flow Technology Device 
An LFT device used in a method for analysis of the analyte 
40 
32 is provided. An exemplary method for preparing the 
sample 26 has at least the steps of grinding a plant tissue 
sample, performing the LFT assay with the LFT device 10, 
and taking a sample disc 48 from the LFT device 10 for use in 45 
an analytic system. Then, the step of analyzing the analyte 3 2 
in the analysis system is performed. 
The preparation of the sample 26 can be performed with the 
following materials: 
12 
4. Slightly fold the opening of the bag to prevent spilling 
while grinding the plant tissue inside the bag using a 
tissue homogenizer (Agdia ACC 00900 or alternative). 
5. Grind the plant tissue until the tissue is completely 
macerated and the extracted solution becomes translu-
cent. 
The step of performing the LFT assay with the LFT device 
10 can be performed with the cassette 58 or without the 
cassette 58. When using the LFT device 10 without the cas-
sette 58, pipette 0.5 ml of the extracted solution into a 1.5 ml 
Eppendorftube. Place the sample pad 12 of the LFT device 10 
in the extracted solution in the Eppendorf test tube and allow 
the solution to move upward until it reaches the wick (-3 
minutes.). After the flow migration, remove the LFT device 
10 from the Eppendorf tube. Subsequently, take the punch 48 
from the membrane 14 of the LFT device 10. Subsequently, 
either obtain a 1.2 mm sample disc 48 or allow the membrane 
to dry in a clean Petri dish for 3 to 10 minutes. This 3 to 10 
minutes drying is optional because the assay works well in 
both ways wet or dry. However, when the soluble paper is dry 
it might be easier to punch and manipulate and some user 
would prefer to wait, but it works well in both ways. 
When using the LFT device 10 inside the cassette 58, 
pipette 0.5 ml of the extracted solution into the well 72 of the 
cassette 58, then allow the extracted solution to flow towards 
the wick (-3 minutes). Subsequently, take the punch 48 from 
the membrane 14 of the LFT device 10. Subsequently, either 
obtain a 1.2 mm sample disc 48 or allow the membrane to dry 
in a clean Petri dish for 3 to 10 minutes. 
The step of taking sample disc 48 from the LFT device 10 
for analysis, such as by the PCR or ELISA technique, can be 
accomplished by the following steps: 
1. Take 1.2 mm sample disc 48 from the membrane 14 by 
punching it out using a puncher ( e.g., Whatman® Harris 
Uni-Core™ 1.2 mm or alternative). 
2. Place the punch 48 directly into a tube for PCR or a 
ELISA microplate well. 
Then, the PCR or ELISA based assay is performed accord-
ing to any appropriate PCR or ELISA protocol. 
Exemplary Water Soluble Biomaterial 
A series of experiments were carried out to assess the 
physical properties of a variety of water soluble biomaterial 
("WSB") that can be used for the membrane 14 in the LFT 
device 10. The WSB used for the experiments were obtained 
from Aquasol® Corporation (North Tonawanda, N.Y.). The 
WSB are identified by Aquasol® as ASW-15, ASW-25, 
ASW-50, ASW-DC, and ASW-240. The thickness of ASW-
lxPBST (Phosphate buffer saline tween-20); 
Sample mesh bag (Agdia ACC 00930 or alternative); 
Tissue Homogenizer (AgdiaACC 00900 or alternative); 
50 15 is 50 µm. ThethicknessofASW-25 is 83 µm. The thickness 
ofASW-50is 76 µm. The thickness ofASW-DC is 50 µm. The 
thickness of ASW-240 is 170 µm. 
the LFT device 10; 
1.5 ml Eppendorf PCR tube; 
and the puncher (e.g., Whatman® Harris Uni-Core™ 1.2 55 
mm) for obtaining the punch 48. 
The step of grinding of the plant tissue can be performed by 
the following steps: 
1. Determine the exact amount of plant tissue and 1 xPBST 
buffer needed. 1 g of plant tissue requires 10 ml of 60 
1 xPBST. Thus, 0.5 g plant tissue needs 5 ml of 1 xPBST. 
2. Place the required volume of lxPBST into a sample 
mesh bag (Agdia ACC 00930 or alternative). 
3. Add the measured amount of plant tissue inside the 
sample mesh bag containing the 1 xPBST. Make sure the 65 
plant tissue is between the mesh inside the bag and 
located near the bottom of the bag. 
In Experiment 1, 10 µl, 15 µl, 20 µl, & 50 µl of water were 
placed on WSB. An ANOVA (Factor 1: WSB and Factor 2: 
amount of water) and Duncan's Multiple Range Test for 
absorbance readings at 260 nanometers ("nm") and 280 nm 
was performed. ASW-15, ASW-25, ASW-50, ASW-DC, and 
ASW-240 were tested. Water was used as control. The 
amount of water used was 10 µl, 15 µl, 20 µl, and 50 µI. The 
thickest material had more residues as measured by the high-
est absorbance, as shown in FIGS. 9 and 10. 
In Experiment 2, a predetermined amount of water was 
applied to a predetermined amount ofWSB. 2, 5, and 10 µl of 
water were placed on WSB surface. An ANOVA (Factor 1: 
WSB and Factor 2: amount of water) and Duncan's Multiple 
Range Test for absorption time was performed. ASW-15, 
ASW-25,ASW-50,ASW-DC, andASW-240weretested. The 
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amount of water used was 2 µl, 5 µl, and 10 µI. The thickest 
WSB absorbed water faster than the thinnest WSB and the 
more water was applied to the WSB the slower the applied 
water was absorbed, as shown in FIGS. 11 and 12. 
In Experiment 3, a predetermined amount of water was 5 
applied to a WSB. AnANOVA (Factor 1: WSB and Factor 2: 
amount of water) and Duncan's Multiple Range Test for 
water spot diameter was performed. ASW-15, ASW-25, 
ASW-50, ASW-DC, andASW-240 were tested. The amount 
10 of water used was 2 µl, 5 µl, and 10 µI. The more water was 
14 
At step SE, dropping 25 µl ofO.lM phosphate buffer onto 
the WSB treated area cleans the treated area, and the phos-
phate buffer was let stand for 20 minutes. 
At step SF, performing a series of dehydration stages on the 
WSB treated area by dropping 30% EtOH and letting stand 
for 15 minutes, then dropping 50% EtOH and letting stand for 
15 minutes, then dropping 70% EtOH and letting stand for 15 
minutes, then dropping 90% EtOH and letting stand for 15 
minutes, then dropping 95% EtOH and letting stand for 15 
minutes, and then dropping 100% EtOH and letting stand for 
15 minutes, and then dropping on the WSB treated area once 
again 100% EtOH and letting stand for 15 minutes. 
Under SEM, the analyte 32, which in this experiment is 
applied to the WSB the larger was the spot. No holes were 
made in the WSB with any of the water volumes tested 
wherein "holes" is defined as a perforation, fissure, crack or 
fiber gap visible to the naked eye. 
In Experiment 4, the objective was to determine surface 
appearance, i.e., changes in a matrix of porosity, ofWSB and 
compare "dry" WSB versus "wet" WSB; and to assess WSB 
15 bacteria, was found on a surface or the storage pockets of the 
ASW-15,ASW-25, andASW-240. ASW-25 provided the best 
fixation images under SEM. No bacteria were found on the 
surface or storage packets of the ASW-50 and ASW-DC. In 
for the presence of pore spaces that may serve as storage 
pockets for the analyte 32, such as microorganisms and 20 
nucleic acids. ASW-15, ASW-25, ASW-50, ASW-DC, and 
ASW-240 were tested. For the "dry" WSB, a small piece of 
WSB was selected and treated with Gold/Palladium (Au/Pd) 
coating as known to one skilled in the art. For the "wet" WSB, 
10 µl of H2O was applied to the WSB and allowed to dry. 25 
Then, a small piece of WSB was selected and treated with 
Gold/Palladium (Au/Pd) coating as known to one skilled in 
the art. The samples of membranes used for SEM analysis 
were of square pieces of 13 mmx13 mm. Quanta 600F Field 
Emission Gun Scanning Electron Microscope ("SEM") 30 
(Hillsboro, Oreg.) was used to analyze the "dry" WSB and 
"wet"WSB atmagnification=l00x, Spot=3.0, andHV 10.00 
kV. Under SEM, the organization of the fibers in the "wet" 
WSB is more scattered than in the "dry" WSB, and wetting 
35 
the WSB caused changes in the physical structure of the WSB 
such that potential storage pockets are present. Measure of 
porous size were done and there were not dramatic changes 
after wetting. 
addition, "salt" particles were detected in some SEM images. 
Without being bound by the theory, the "salt" particles were 
possibly present on the SEM images because the fixation 
procedure was performed by dropping reagents onto the WSB 
rather than soaking the WSB. 
PCRAnalysis Using Water Soluble Biomaterial 
A series of experiments were carried out to determine 
whether the WSB substantially inhibits with PCR reactions 
when the analyte 32 bound to the membrane 14 of the LFT 
device 10 is placed in the analysis system for PCR analysis. 
ASW-15, ASW-25, ASW-50, ASW-DC, andASW-240 were 
tested. A Microfuge i.e., a "bench top centrifuge," (Beckman 
Instruments, Inc.; Eppendorf, centrifuge 5418) was used. A 
PCR machine, namely PTC-200 Thermo Cycler (MJ 
Research, Inc.), was prepared. A puncher (Whatman® Harris 
Uni-Core™) was used to obtain discs for PCR amplification. 
In Experiment 6, the objective is to determine whether the 
WSB substantially inhibits with PCR reactions. The exem-
Fixation of Analytes in Water Soluble Biomaterial 
In Experiment 5, the objective was to fix an analyte 32 in a 
storage pocket in the WSB and view the fixed analyte and the 
storage pocket under SEM. ASW-15, ASW-25, ASW-50, 
ASW-DC, andASW-240 were tested. The exemplary analyte 
32 was a bacteria, specifically Pseudomonas syringae pv. 
tomato DC3000. 
40 plary method steps of a protocol for PCR analysis using 
analyte 32 fixed to the WSB is commenced. The exemplary 
analyte was a viral ds-RNA ( double strand RNA), specifically 
CiLV-C (Citrus leprosis virus C) at 400 ng/µl concentration. 
Step 6A includes spotting 1 µl of a viral RNA on the WSB is 
45 performed. 
Step 6B includes obtaining 1.2 mm disc of the viral spotted 
WSB. Step 6C includes adding the 1.2 mm disc of each of the 
viral spotted WSBs to a separate PCR test tube containing 
RT-PCR reaction mix. The exemplary 20 µl of RT-PCR reac-The exemplary method steps of a process for a protocol 
used for fixation of the bacteria to the WSB is commenced at 
step SA by treating a WSB with 10 µl of a bacterial culture of 
Pseudomonas syringae pv. tomato DC3000. 
50 tion mix: 
In common practice by one skilled in the art, a fixation 
procedure for the analyte 32 includes soaking the analyte 32 
and the membrane 14 in a series of reagents; however, the 55 
WSB is soluble so "dropping" 25 µl of the reagents was done 
instead. 
At step SB, dropping 25 µl of 2% glutaraldehyde onto the 
WSB treated area acts as a primary fixation, and the glutaral-
dehyde was let stand for 45 minutes. 60 
sterile nuclease-free water, 3.2 µl; 
2x Reaction mix (Invitrogen), 10.0 µl; 
RNAsin Plus 40 U/µl, 1.0 µl; 
5 µM Forward Primer, 2.0 µl; 
5 µM Reverse Primer, 2.0 µl; 
SuperScript™ III One-Step RT-PCR System with Plati-
num® Tag DNA Polymerase (Invitrogen™ 12574-026) 
Mix, 0.8 µl; 
and albumin from bovine serum (SIGMA-ALDRICH® 
A 7888) at 10 µg/µl, 1.0 µI. 
At step SC, dropping 25 µl of0.lM phosphate buffer onto 
the WSB treated area cleans the treated area, and the phos-
phate buffer was let stand for 20 minutes. Process step SC is 
repeated before moving onto process step SD. 
At step SD, dropping 25 µl of 1 % OsO4 solution onto the 
WSB treated area acts as a secondary fixation, and the phos-
phate buffer was let stand for 45 minutes. 
Thus, each test tube for the RT-PCR reaction contains 20 µl 
65 ofRT-PCRmix and the 1.2 mm disc of the viral spotted WSB. 
In Step 6D, there is running a RT-PCR reaction under the 
conditions, as shown in the table 1 below: 




Temperature Time Number of Cycles 
16 
In Step SJ, there is running a RT-PCR reaction under the 
conditions, as shown in table X, for each separate PCR test 

















In Step SK, there is loading PCR products from each test 
5 tube from the RT-PCR reaction in separate preparations of 
1.0% Agarose gel and running electrophoresis on the PCR 
products for 90 minutes at 90 Volts. 
Final Elongation 720 C. 7 minutes 
In Step 6E, there is loading PCR products from each test 
tube from the reverse transcription PCR (RT-PCR) reaction in 
separate preparations of 1.0 to 2% Agarose gel in 1 xTBE 
(Tris base, boric acid and EDTA) and running electrophoresis 
on the PCR products for 90 minutes at 90 Volts. Visualization 
was made by incorporating SYBr green to the agarose gel. 
The observation was made upon ultraviolet (UV) light. 
As shown in Table 2 below,ASW-15,ASW-25, andASW-
50 did not interfere with PCR amplification up to the fourth 
10 dilution. 
Amplification by RT-PCR was successful using the viral 
spotted ds-RNA as the PCR template. In other words, the 
WSB does not substantially inhibit the PCR reaction. 
In Experiment 7, the objective is to determine whether the 
WSB substantially inhibits PCR product quantification. 
ASW-25, ASW-50, and ASW-DC were tested. 
15 
20 
The exemplary method steps of a protocol for PCR product 
quantification using analyte fixed to the WSB is commenced. 25 
Step 7 A is loading 2 µl of PCR product from Experiment 6 in 
the NanoDrop® ND-1000 Spectrophotometer (Thermo Sci-
entific of Wilmington, Del.), Nucleic Acid-DNA option for 
each PCR product produced from each WSB. Step 7B is 30 
quantifying each PCR product produced from each WSB. 
The DNA quantification results were ASW-25, 379.7 ng/µl; 
ASW-50, 384.8 ng/µl; andASW-DC, 365.9 ng/µl for. Recall 
that the viral ds-RNA tested was CiLV-C, 400 ng/µ1. Thus, the 
WSB does not substantially inhibit the PCR reaction tech- 35 
nique for quantification of PCR reaction product. 
In Experiment 8, the objective is to determine what con-
centrations of DNA fixed to WSB can be amplified by PCR. 
ASW-15, ASW-25, ASW-50, ASW-DC, andASW-240 were 
tested. The template is Pythium spinosum ("PS-1 "), 10 ng/µ1. 40 
The exemplary method steps of a protocol for serial dilu-
tion of DNA template and testing PCR amplification sensi-
tivity is commenced. Step SA is transferring 10 µl to PS-1 to 
a test tube A. Step SB is transferring 1 µl from the test tube A 
to a test tube B that has 9 µl ofH20 for 10 µl total volume in 
45 
test tube B. Step SC is transferring 1 µl from the test tube B to 
a test tube C that has 9 µl ofH20 for 10 µl total volume in test 
tube C. Step SD is transferring 1 µl from the test tube C to a 
test tube D that has 9 µl ofH20 for 10 µl total volume in test 50 
tube D. Step SE is transferring 1 µl from the test tube D to a 
test tube E that has 9 µl of H20 for 10 µl total volume in test 
tube E. Step SF is transferring 10 µl ofH20 to a test tube F. 
Steps SA to SF are repeated for each WSB tested. 
At step SG, 1 µl from each of the test tubes SF is spotted on 55 
the WSB. Step SG is repeated for each WSB tested. 
At step SH, a 1.2 mm disc of the spotted WSB area is taken 
by the puncher. Step SH is repeated for each WSB tested. 
Step SI is adding each of the 1.2 mm discs from each of the 
spotted WSB to separate PCR test tube for each spotted WSB 60 
sample. The control has no WSB and 1 µl plasmid DNA for 
each concentration. The exemplary 20 µl ofRT-PCR reaction 
mix: 
sterile nuclease-free water, 8 µl; 
TABLE2 
Sam le 
ASW- ASW- ASW- ASW- ASW- Positive 
Tube 15 25 50 DC 240 CONTROL 
A + + + + + + 
B + + + + + + 
C + + + + + + 
D + + + + + 




The + signifies a positive result, i.e., PCR amplification 
successful. The - signifies a negative result, i.e., PCR ampli-
fication unsuccessful. The F test tube was a negative control 
for each of ASW-15, ASW-25, ASW-50, ASW-DC, and 
ASW-240, i.e., tube Fis the negative control, it is required to 
demonstrate the WSB is not reactive or contaminated. 
Exemplary Sample Pad Materials 
After the format for the LFT device 10 was developed as 
shown in FIG. 7, a series of experiments were conducted to 
search for the best material for the sample pad 12. The sample 
pad 12 and the wick 16 were made from the same material. 
The membrane 14 was made fromASW-25. The sample pads 
12 were 26 mm long. The membranes 14 were 25 mm long. 
The wicks 16 were 21 mm long. The sample pads 12, the 
membranes 14, and the wicks 16 were 4 mm wide. The holder 
46 was provided oflength 8 mm on the backing card of75 mm 
length and 4 mm width. See FIG. 7 for length and width 
orientations.A test solution oflxPBST 500 µl with 15 µl dye 
was used. 
The objective of Experiment 9 was to determine which 
materials tested would produce fast flow through the LFT 
device 10. The materials tested for the sample pad 12 
included: Ahlstrom (Helsinki, Finland) 1660, 1662, 1663, 
6615; Millipore (Billerica, Mass. USA) C048, C0083, G041; 
and Whatman (Whatman pie, UK) 16-S, 470, 2668, 2727, 
CF6, Fusion 5™ GF33, GB002, GF/D, Standard 17. ASW-
15, ASW-25, ASW-50, ASW-DC, and ASW-240 were also 
tested for the sample pad 12, although it was found that 
making the sample pad 12, the membrane 14, and the wick 16 
from a single continuous piece was impractical, because the 
bottom part of the continuous piece that soaked in the test 
solution dissolved and mixed in the solution. Millipore C083; 
and Whatman GF33, GB002, and Standard 17 were good 
candidates for the sample pad 12 with wicking rate less than 
4 minutes. In an exemplary embodiment, the less than 4 
minute is preferable to reduce the possibility that the WSB in 
the membrane, in this case ASW-25, will dissolve in the 
GoTaq mix (Promega Corporation, Madison, Wis.), 10 µl; 
10 µM Forward Primer, 1 µl; and 
65 solution during the wicking process. 
10 µM Reverse Primer, 1 µI. 
In experiment 10, the four candidate materials for the 
sample pad 12 were tested again. Millipore C083 had the 
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lowest wick rate and the smallest standard deviation when 
each of the good candidates were tested 10 times each· there-
fore, Millipore C083 was selected for the sample pad 12 in the 
LFT device 10 in one other exemplary embodiments. The 
Millipore C083 wicking rate mean is 2.9417 minutes. The 5 
Whatman Standard 17 wicking rate mean is 3.2266 minutes. 
The Whatman GB002 wicking rate mean is 3.7321 minutes. 
The Whatman GF33 wicking rate mean is 3.7928 minutes. 
In other words, an exemplary embodiment includes a 
method comprising, the steps of: flowing a sample 26 solution 10 
that cont~ins an analyte 32 through an LFT device 10 config-
ured to bmd the analyte 32; punching a sample disc 48 that 
binds the analyte 32 from the LFT device 10; and placing the 
sample disc 48 directly in an analysis system for analysis of 
the analyte 32, in which the step of placing the sample disc 48 15 
is not preceded by a step of eluting the analyte 32 from the 
sample disc 48. A second embodiment includes the LFT 
device 10 includes at a least water soluble paper that binds the 
analyte 32, and the sample disc 48 is punched from the water 
soluble paper. A third embodiment includes the analysis sys- 20 
tern includes at least an analysis technique selected from a 
gro~p consisting of polymerase chain reaction ("PCR"), and 
the mitial denaturation is a predetermined prolonged interval 
selected to promote the PCR. A fourth embodiment includes 
the step of flowing a sample 26 solution is preceded by at least 25 
the steps of: measuring a predetermined amount of a sample 
26 material; calculating a volume of a solution responsive to 
!he predetermined am~unt of the sample 26 material; provid-
mg a sample bag to which the volume of the solution is added· 
adding the predetermined amount of the sample 26 material 30 
to the solution in the sample bag; and grinding the sample 26 
material in the bag until it is macerated and the solution is 
translucent to prepare the sample 26 solution. 
While the invention has been described in connection with 
an exemplary embodiment, it is not intended to limit the scope 35 
of the invention to the particular form set forth, but on the 
contrary, it is intended to cover such alternatives modifica-
tions, and equivalents as may be included within the spirit and 
scope of the invention as defined by the appended claims. 
I~ will be clear that the present invention is well adapted to 40 
attam the ends and advantages mentioned as well as those 
inherent therein. While presently preferred embodiments 
have been described for purposes of this disclosure, numer-
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ous changes may be made which will readily suggest them-
selves to those skilled in the art and which are encompassed 
by the appended claims. 
What is claimed is: 
1. An apparatus comprising: 
a backing card; 
a sample pad adhered to said backing card; 
a wick adhered to said backing card and spaced apart from 
said sample pad; 
a water soluble membrane situated between said sample 
pad and said wick and in communication with both said 
sample pad and said wick, said membrane comprising an 
affixed portion and an unaffixed portion, said affixed 
portion being secured to said backing card such that said 
unaffixed portion is at least large enough to permit a 
punch to extract a sample therefrom without including 
any of said affixed portion in the sample, wherein there 
is a gap between at least a portion of said membrane and 
said backing card; 
wherein said membrane binds an analyte from a sample 
that flows through a flow path defined by said sample 
pad, through said membrane to said wick- and 
wherein said unmounted portion of said m~mbr~ne does 
not substantially inhibit analysis of the analyte when 
placed in an analysis system. 
2. The apparatus of claim 1, wherein: 
said unmounted portion of said membrane is water soluble 
paper. 
3. The apparatus of claim 1, wherein: 
said unmounted portion of said membrane includes at least 
sodium carboxy methyl cellulose. 
4. The apparatus according to claim 1 further comprising: 
a housing surrounding said backing card, sample pad, wick 
and membrane to facilitate long term storage. 
5. The apparatus of claim 1, further comprising: 
a biologic marker attached to said membrane concentrates 
said analyte in a predetermined sample collection region 
of said membrane by an assay format chosen from a 
group consisting of direct, competitive, and boulder in 
the stream. 
6. The apparatus of claim 5, in which said biologic marker 
is a specific antibody targeted to said analyte. 
* * * * * 
